MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
STAAR Surgical Company Revenue 2011-2026 | STAA
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue STAAR Surgical Company
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 314 M | 322 M | 284 M | 230 M | 150 M | - | 124 M | 90.6 M | 77.1 M | 75 M | 72.2 M | - | 63.8 M | 62.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 322 M | 62.8 M | 156 M |
Quarterly Revenue STAAR Surgical Company
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 94.7 M | 44.3 M | 42.6 M | - | 88.6 M | 99 M | 77.4 M | - | 80.3 M | 92.3 M | 73.5 M | - | 76 M | 81.1 M | 63.2 M | 59 M | 58.4 M | 62.4 M | 50.8 M | 38.9 M | 47.1 M | 35.2 M | 35.2 M | - | 39.1 M | 39.7 M | 32.6 M | 31.2 M | 31.8 M | 33.9 M | 27.1 M | 24.9 M | 23.5 M | 21.9 M | 20.4 M | 22.1 M | 20.1 M | 21 M | 19.3 M | 16.6 M | 18.8 M | 18.7 M | 18.9 M | 18.9 M | 18.2 M | 20 M | 20.2 M | - | 17.1 M | 18.2 M | 18 M | 16.5 M | 15.9 M | 15.9 M | 15.5 M | 16.4 M | 15.3 M | 16.3 M | 14.8 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 99 M | 14.8 M | 37.7 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical instruments industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Baxter International
BAX
|
2.75 B | $ 19.11 | -0.98 % | $ 9.75 B |  USA |
 |
Becton, Dickinson and Company
BDX
|
21.8 B | $ 194.07 | -0.8 % | $ 55.8 B | USA |
 |
Luminex Corporation
LMNX
|
417 M | - | - | $ 1.75 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
17.9 M | $ 8.64 | -18.34 % | $ 174 M | USA |
 |
Akers Biosciences, Inc.
AKER
|
1.58 M | - | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
150 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
1.02 B | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
106 M | - | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
2.88 B | - | -0.05 % | $ 10.3 B | USA |
 |
Harvard Bioscience
HBIO
|
112 M | $ 0.67 | 1.66 % | $ 28.4 M | USA |
 |
Varian Medical Systems, Inc.
VAR
|
3.17 B | - | -0.02 % | $ 16.3 B | USA |
 |
Alcon
ALC
|
9.91 B | $ 78.81 | -0.64 % | $ 40.4 B |  Schweiz |
 |
Repro Med Systems
KRMD
|
28.5 M | $ 5.81 | 2.11 % | $ 265 M | USA |
 |
AtriCure
ATRC
|
465 M | $ 39.56 | -1.54 % | $ 1.86 B | USA |
 |
Atrion Corporation
ATRI
|
169 M | - | - | $ 810 M | USA |
 |
ICU Medical
ICUI
|
2.38 B | $ 142.67 | -1.36 % | $ 3.48 B | USA |
 |
electroCore
ECOR
|
16 M | $ 4.49 | -3.55 % | $ 24.8 K | USA |
 |
iRhythm Technologies
IRTC
|
592 M | $ 177.44 | -0.63 % | $ 5.54 B | USA |
 |
AngioDynamics
ANGO
|
292 M | $ 12.84 | -1.23 % | $ 525 M | USA |
 |
Isoray
ISR
|
3.55 M | - | 0.03 % | $ 108 M | USA |
 |
The Cooper Companies
COO
|
4.09 B | $ 81.96 | -0.62 % | $ 16.3 B | USA |
 |
Glaukos Corporation
GKOS
|
315 M | $ 112.91 | -1.16 % | $ 5.47 B | USA |
 |
LeMaitre Vascular
LMAT
|
220 M | $ 81.1 | -2.3 % | $ 1.82 B | USA |
 |
Haemonetics Corporation
HAE
|
1.36 B | $ 80.15 | -1.02 % | $ 4.03 B | USA |
 |
InfuSystem Holdings
INFU
|
110 M | $ 8.97 | 0.67 % | $ 185 M | USA |
 |
Masimo Corporation
MASI
|
2.09 B | $ 130.06 | -0.77 % | $ 6.93 B | USA |
 |
Merit Medical Systems
MMSI
|
1.36 B | $ 88.14 | -0.47 % | $ 5.13 B | USA |
 |
OraSure Technologies
OSUR
|
186 M | $ 2.42 | -2.02 % | $ 180 M | USA |
 |
Intuitive Surgical
ISRG
|
8.35 B | $ 566.36 | -1.09 % | $ 201 B | USA |
 |
Microbot Medical
MBOT
|
117 K | $ 2.0 | -2.44 % | $ 20.4 M |  Israel |
 |
Milestone Scientific
MLSS
|
8.63 M | $ 0.27 | -0.22 % | $ 21.5 M | USA |
 |
Nephros
NEPH
|
14.2 M | $ 4.88 | 3.39 % | $ 50.7 M | USA |
 |
Stereotaxis
STXS
|
26.8 M | $ 2.3 | -0.22 % | $ 186 M | USA |
 |
NeuroMetrix
NURO
|
3.03 M | - | 5.05 % | $ 9.02 M | USA |
 |
Envista Holdings Corporation
NVST
|
2.51 B | $ 21.71 | -0.91 % | $ 3.74 B | USA |
 |
STERIS plc
STE
|
5.46 B | $ 253.52 | -0.76 % | $ 25 B | USA |
 |
Pro-Dex
PDEX
|
66.6 M | $ 38.48 | -0.3 % | $ 127 M | USA |
 |
Predictive Oncology
POAI
|
1.62 M | - | - | $ 32.4 M | USA |
 |
Pulse Biosciences
PLSE
|
700 K | $ 13.73 | 0.22 % | $ 660 M | USA |
 |
Utah Medical Products
UTMD
|
12.3 M | $ 55.96 | -0.57 % | $ 203 M | USA |
 |
ResMed
RMD
|
3.58 B | $ 240.87 | -0.91 % | $ 35.2 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
3.79 B | $ 11.43 | 0.35 % | $ 2.32 B | USA |
 |
Repligen Corporation
RGEN
|
632 M | $ 163.86 | -1.64 % | $ 9.13 M | USA |
 |
BioLife Solutions
BLFS
|
82.3 M | $ 24.18 | -1.95 % | $ 1.11 B | USA |
 |
Retractable Technologies
RVP
|
33 M | $ 0.77 | -0.63 % | $ 23.1 M | USA |
 |
Teleflex Incorporated
TFX
|
3.05 B | $ 122.04 | 0.35 % | $ 5.72 B | USA |
 |
West Pharmaceutical Services
WST
|
2.89 B | $ 275.14 | -0.62 % | $ 20.1 B | USA |